Articles tagged with: Leukemia & Lymphoma Society
NewsFlash »
Give And Get Campaign Results – The Gap Give and Get Campaign, which benefited The Leukemia & Lymphoma Society (LLS), was held from July 30 to August 2. The Gap is donating 5 percent of its sales during this period to the LLS, raising a total of $500,000 to support blood cancer research. For more information, please visit the LLS Web site.
Royal Hospital In Oman Setting Up Stem Cell Bank And Transplantation Unit – The Royal Hospital in Oman is in the final stages of establishing a stem cell bank and a transplantation unit. The stem cell bank will be ready by the end of 2009, and the transplantation unit will be completed by September 2010. Currently, building modifications are under way to accommodate the stem cell bank. The equipment for the stem cell bank has been selected and will be installed once the building modifications are completed. For more information, please visit the Zawya article.
Keryx To Present Overview Of Leading Drug Candidates – On September 9 at 2:50 p.m., Keryx will present an overview of its leading drugs at the Rodman & Renshaw Annual Global Investment Conference in New York City. Ron Bentsur, Chief Executive Officer of Keryx, will give the presentation on the lead drug candidates perifosine (KRX-0401) and Zerenex (ferric citrate). Perifosine is currently in trials as an oral anti-cancer drug that affects the growth and death of multiple myeloma cells, while Zerenex is in trials as a treatment for elevated phosphate levels in patients with severe kidney disease. The presentation will be available live by audio webcast at the Keryx Web site. For more information, please visit the Keryx press release.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Research Confirms MGUS Is Linked To Myeloma, But May Not Be Linked To As Many Diseases As Previously Thought – According to a study published in the August 2009 issue of Mayo Clinic Proceedings, monoclonal gammopathy of undetermined significance (MGUS) may not be linked to as many serious diseases as previously thought. MGUS is a symptomless blood disorder that is a precursor of multiple myeloma. This study confirmed a link between MGUS and 14 diseases. However, before this study, it was also thought to be a precursor for many more diseases. These Mayo Clinic findings may save patients from unnecessary tests and treatment. For more information, please see the Mayo Clinic press release.
Lawsuit Claims Celgene Corporation Misappropriated The Idea Behind Thalidomide – On August 24, Beth R. Jacobson filed a lawsuit against Celgene Corporation claiming “misappropriation of an idea” and “unjust enrichment” concerning the company’s sale of thalidomide (Thalomid) and Revlimid (lenalidomide) for the treatment of myeloma. The suit claims that Jacobson developed the original idea for treating myeloma with thalidomide and is consequently entitled to compensation based on established legal precedent. Jacobson seeks a minimum of $300 million in past damages and 25 percent of the future profits from the sale of Celgene’s thalidomide products. For more information, please see Ms. Jacobson's press release.
Light The Night Walks – On September 11, the Leukemia & Lymphoma Society (LLS) will hold Light the Night Walks in St. Louis and St. Peters, MO. Participants will walk along a two- or three-mile route, carrying a lighted balloon, in support of those touched by blood cancer. For more information, please visit the LLS Web sites for each of the events.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Senesco Acquires More Funding For Possible Myeloma Treatment - On July 29, Senesco Technologies acquired approximately $705,000 from Senesco’s Board of Directors and other investors, including Cato Holding Company, to fund its SNS-01 development program. SNS-01 is a multiple myeloma drug candidate that has shown promising results in mice. Senesco intends to use these funds primarily for multiple myeloma research and for starting a Phase 1 clinical trial in the SNS-01 program. For more information, please see the Senesco Technologies press release.
First Connection Training - On August 22 the Leukemia & Lymphoma Society (LLS) is holding an event to provide cancer survivors an opportunity to support current cancer patients in the First Connection Program. This session will teach volunteers the ways to interact with patients who are seeking support, and will feature Janine E. Gauthier, Ph. D., the director of Psychosocial Oncology at Rush University Medical Center. For more information, please visit the LLS Website.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
D.C. Ride-a-thon – On August 1, Jim Barth, a multiple myeloma patient, will begin his ride on his scooter from Clearwater, FL to the International Myeloma Foundation (IMF) Seminar in Washington, D.C. Jim is looking for sponsors to help raise funds for the IMF and the Tampa – St. Petersburg Multiple Myeloma Education Group. The IMF Seminar will be held on August 7 and 8. For more information, please visit Jim’s Web site. Donations may be made on his page.
5430 Long Course Triathlon – On August 9, the 5430 Long Course Triathlon will begin at 6:30 a.m. and end at 3:30 p.m. The triathlon will be held in Boulder, CO, and the Leukemia & Lymphoma Society’s Team In Training (TNT) will be participating. To join Team In Training for the Triathlon, please visit the TNT Web site.
Ontario Approves Funding For Revlimid – On July 24 the Ontario government approved funding for Revlimid (lenalidomide) to be used with dexamethasone (Decadron) for multiple myeloma patients. This makes Ontario the second Canadian province to fund Revlimid, following British Columbia. Myeloma Canada is now urging other provinces to follow the examples set by the two provinces. For more information, please visit the CNW Group Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
1st Annual Ronnie Marshall Memorial Poker Run For Multiple Myeloma – In an interesting twist on multiple myeloma fundraisers, there will be a poker run on July 25 beginning at CJ’s Backroom in Lusby, MD. A poker run is an organized motorcycle ride in which riders stop at five checkpoints along the designated route. At each checkpoint, the rider draws a card and records the card on a score sheet. At the end of the route the person with the best poker hand is the winner. Registration for this fundraiser will take place from 10 a.m. to noon. The ride fee is $20. For more information, please visit the Let's Ride Web site.
LLS and FORMA Therapeutics Collaborate To Bring New Therapies To Patients Faster – On July 20 The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics announced their partnership to accelerate LLS research projects focused on therapies for blood cancer patients. Ten small molecule candidates discovered by LLS grant-funded academic researchers are going to be analyzed by FORMA’s advanced technology to find which molecules are best suited for clinical trials. This partnership is the latest in the LLS’s Therapy Acceleration Program that is meant to move potential therapies quickly through the FDA drug approval process. For more information, please see the FORMA Therapeutics press release.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
Fill The House For LLS – On July 1, the Cleveland Indians baseball team is sponsoring a fundraiser event that will benefit the Leukemia & Lymphoma Society (LLS). This event will take place at Progressive Field at 7 p.m, and the tickets will cost $16 if purchased from the LLS, otherwise $22. The Indians will donate $5 for each ticket sold by the LLS and $1 for every other ticket purchased. For more information or to purchase tickets, please visit the LLS Web site.
Institutional Insights – On July 23, this educational program sponsored by the Multiple Myeloma Research Foundation (MMRF) will take place at The Westin Copley Place in Boston. The program will take place from 10:30 a.m. to 2 p.m. Topics to be discussed at the program include advances in diagnosis, frontline therapy, stem cell transplant, managing relapse and bone disease, as well as supportive care. For more information, please visit the MMRF Web site.
BiovaxID Vaccine Released in Europe - BiovaxID is a vaccine with the potential to treat B-cell blood cancers, such as multiple myeloma. BioVest International released this vaccine, currently used for follicular non-Hodgkin's lymphoma, on a named-patient basis in Europe. A named-patient program allows qualifying patients to receive investigational drugs before being approved by the European Medicines Evaluation Agency. For more information, please see the BioVest press release.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
NewsFlash »
San Diego International Triathlon – On June 28, the 26th annual San Diego International Triathlon will begin at 5:15 a.m. and end at noon. The race will be held at Spanish Landing Park, and The Leukemia & Lymphoma Society's Team In Training (TNT) will be participating. The race benefits St. Vincent de Paul Village, America’s top rehabilitation center for homeless and those in need. To join Team In Training for the triathlon, visit the TNT Web site.
The Price Of Life – Directed by Adam Wishart, this BBC documentary is the first to film the decision-making process of the National Institute for Health and Clinical Excellence (NICE). NICE is an independent organization that provides medical opinions to the National Health Service (NHS), the government-funded health care system in the U.K. The documentary gives insight into NICE’s process of deciding whether or not Revlimid (lenalidomide) should be approved for use and funded by the NHS. It also gives the perspective of patients and an American drug company. For more information, please visit BBC Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
